Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05048719 | A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus | PHASE2 | COMPLETED | 383 | — | — | Sep 15, 2021 | Sep 30, 2022 | Oct 17, 2023 | 44 | United States, Hungary +3 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Country + Baseline HbA1c Group (\<=8.0%, \>8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| Arm | Type | Description |
|---|---|---|
| 3 milligrams (mg) LY3502970 | EXPERIMENTAL | Participants received maintenance dose of 3 mg with dose escalation starting from 2 mg LY3502970 administered orally once daily (QD). |
| 12 mg LY3502970 | EXPERIMENTAL | Participants received maintenance dose 12 mg with dose escalation starting from 2 mg, 6 mg and then 12 mg LY3502970 administered orally QD. |
| 24 mg LY3502970 | EXPERIMENTAL | Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally QD. |
| 36 mg LY3502970 - 1 | EXPERIMENTAL | Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD. |
| 36 mg LY3502970 - 2 | EXPERIMENTAL | Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally QD. |
| 45 mg LY3502970 - 1 | EXPERIMENTAL | Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD. |
| 45 mg LY3502970 - 2 | EXPERIMENTAL | Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD. |
| 1.5 mg Dulaglutide | ACTIVE_COMPARATOR | Participants received 1.5 mg Dulaglutide administered subcutaneously (SC) once weekly (QW). |
| Placebo | PLACEBO_COMPARATOR | Participants received matching placebo. |
| Name | Type | Description |
|---|---|---|
| LY3502970 | DRUG | Administered orally |
| Dulaglutide | DRUG | Administered subcutaneously |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Have been diagnosed with Type 2 Diabetes on diet and exercise and/or a stable dose of metformin * Have a stable body weight for the 3 months prior to randomization * Have a body mass index (BMI) ≥23 kilogram/square meter (kg/m²) * Males must agree to use highly effective metho...